Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press103610.17650/1726-9776-2008-4-4-49-52DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железыTaxoter as a new standard for treatment of hormone-refractory prostate cancerТаксотер® — новый стандарт лечения гормонорефрактерного рака предстательной железыRusakovI. G.РусаковИ. Г.
Russian Federation
AlekseyevB. Ya.АлексеевБ. Я.
Russian Federation
VereshaginaG. V.ВерещагинГ. В.
Russian Federation
GritskevichA. A.ГрицкевичА. А.
Russian Federation
P.A. Gertzen Moscow Research Institute of OncologyМНИОИ им. П.А. Герцена301220084449521302202013022020https://oncourology.abvpress.ru/oncur/article/view/1036

One of the options in the treatment of hormone-refractory prostate cancer is the administration of cytostatic agents. This article addresses the Taxoter — one of the cytostatic agents. Clinical studies discussed in the article have demonstrated the high activity and efficacy of the agent which allows using it in the treatment of hormone-refractory prostate cancer.

.

1. Чиссов В.И. Онкологическая заболеваемость и смертность. М.; 2008.Чиссов В.И. Онкологическая заболеваемость и смертность. М.; 2008.2. Garnick M.B. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993;118:804—18.Garnick M.B. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993;118:804—18.3. Abrahamson P.-A. Revolutions in the management of hormone-refractory prostate cancer. Eur Urol Suppl 2003;2:1—2.Abrahamson P.-A. Revolutions in the management of hormone-refractory prostate cancer. Eur Urol Suppl 2003;2:1—2.4. Stein C.A. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999;26:3—7.Stein C.A. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999;26:3—7.5. Eisenberger M.A., Simon R., O'Dwyer P.J. et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985;3:827—41.Eisenberger M.A., Simon R., O'Dwyer P.J. et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985;3:827—41.6. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormoneresistant prostate cancer. Cancer 1993;71:1098—109.Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormoneresistant prostate cancer. Cancer 1993;71:1098—109.7. Kantoff P.W., Halabi S., Conaway M. et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999;17:2506—13.Kantoff P.W., Halabi S., Conaway M. et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999;17:2506—13.8. Kish J., Bukkapatnam R. et al. The treatment challenge of hormone-refractory prostate cancer. Cancer Care 2001;8(6):487—95.Kish J., Bukkapatnam R. et al. The treatment challenge of hormone-refractory prostate cancer. Cancer Care 2001;8(6):487—95.9. Tannock I.F., deWit R., Berry W.J. et al. Docetaxel plus prednisone or mitoxantron plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502—12.Tannock I.F., deWit R., Berry W.J. et al. Docetaxel plus prednisone or mitoxantron plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502—12.10. Berthold D., Pond G. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 Study. J Clin Oncol 2008;26(2):242—5.Berthold D., Pond G. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 Study. J Clin Oncol 2008;26(2):242—5.11. De Wit R., Eisenberger M.A., Tannock I.F. et al. A multicenter Phase III comparison of docetaxel prednisone (P) and mitoxantrone (MTZ) P in patients with androgen-independent prostate cancer (AIPC): secondary analysis of survival in patient subgroups. Ann Oncol 2004;15(Suppl. 3):abstr 4.De Wit R., Eisenberger M.A., Tannock I.F. et al. A multicenter Phase III comparison of docetaxel prednisone (P) and mitoxantrone (MTZ) P in patients with androgen-independent prostate cancer (AIPC): secondary analysis of survival in patient subgroups. Ann Oncol 2004;15(Suppl. 3):abstr 4.12. Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1515—20.Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1515—20.13. Wildiers H., Highley M.S., de Bruijn E.A., van Oosterom A.T. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003;42:1213—42.Wildiers H., Highley M.S., de Bruijn E.A., van Oosterom A.T. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003;42:1213—42.14. Anderson J., Van Poppel H., Bellmunt J. Chemotherapy for older patients with prostate cancer. BJU Int 2007;99(2):269—73.Anderson J., Van Poppel H., Bellmunt J. Chemotherapy for older patients with prostate cancer. BJU Int 2007;99(2):269—73.15. Piccart M.J., Klijn J., Paridaens R. et al. Steroids to reduce the severity and delay the onset of docetaxel induced fluid retention. Eur J Cancer 1995;31A:575(Suppl 5, abstr 347).Piccart M.J., Klijn J., Paridaens R. et al. Steroids to reduce the severity and delay the onset of docetaxel induced fluid retention. Eur J Cancer 1995;31A:575(Suppl 5, abstr 347).16. Heidenreich A., Schrader A.J. The treatment of hormone-refractory prostate cancer. EAU Update Series 2003;1:40—50.Heidenreich A., Schrader A.J. The treatment of hormone-refractory prostate cancer. EAU Update Series 2003;1:40—50.